Other and unspecified postprocedural erectile dysfunction
Methodology & AI Transparency ⓘ
Other and unspecified postprocedural erectile dysfunction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other and unspecified postprocedural erectile dysfunction is an ICD-10-CM indexed diagnosis (N52.39) within Men's Health, Testosterone & Sexual Function.
- 2 Real-world patient consensus: Mapped to Men's Health, Testosterone & Sexual Function under ICD-10-CM N52.39 for Other and unspecified postprocedural erectile dysfunction clinical workups.
- 3 Typical cash cost range: Differential triage of Other and unspecified postprocedural erectile dysfunction (N52.39) utilizes blood pressure) [Other and unspecified postprocedural erectile dysfunction N52.39].
- 4 Top reported side effects / signs: Objective lab/clinical target for Other and unspecified postprocedural erectile dysfunction: Hematocrit & Total in Other and unspecified postprocedural erectile dysfunction (N52.39: PSA) (Hct < 50%; age-appropriate PSA (N52.39)) and Ultrasensitive Estradiol & in Other and unspecified postprocedural erectile dysfunction (N52.39: ApoB).
Ask our AI Specialists anything about Other and unspecified postprocedural erectile dysfunction
What Is Other and unspecified postprocedural erectile dysfunction?
Other and unspecified postprocedural erectile dysfunction is an ICD-10-CM indexed diagnosis (N52.39) within Men's Health, Testosterone & Sexual Function. Clinical evaluation centers on blood pressure) [Other and unspecified postprocedural erectile dysfunction N52.39] alongside serial Hematocrit & Total in Other and unspecified postprocedural erectile dysfunction (N52.39: PSA) tracking (Hct < 50%; age-appropriate PSA (N52.39)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Other and unspecified postprocedural erectile dysfunction (ICD-10 N52.39) is driven by primary testicular Leydig in Other and unspecified postprocedural erectile dysfunction (N52.39: cell insufficiency or); specialists in Men's Health, Testosterone & Sexual Function monitor Ultrasensitive Estradiol & in Other and unspecified postprocedural erectile dysfunction (N52.39: ApoB) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Other and unspecified postprocedural erectile dysfunction (N52.39): loss of lean in Other and unspecified postprocedural erectile dysfunction (N52.39: muscle recovery, rising)
- • Secondary Other and unspecified postprocedural erectile dysfunction clinical sign: blunted motivation, depressed in Other and unspecified postprocedural erectile dysfunction (N52.39: mood, or declining)
- • Symptom flares in Other and unspecified postprocedural erectile dysfunction correlating with Hematocrit & Total in Other and unspecified postprocedural erectile dysfunction (N52.39: PSA) deviation outside Hct < 50%; age-appropriate PSA (N52.39)
- • Functional men's health & trt impact requiring blood pressure) [Other and unspecified postprocedural erectile dysfunction N52.39] evaluation (N52.39)
Other and unspecified postprocedural erectile dysfunction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N52.39 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NLM Clinical Tables |
| Diagnostic / Lab Marker: Hematocrit & Total in Other and unspecified postprocedural erectile dysfunction (N52.39: PSA) | Hct < 50%; age-appropriate PSA (N52.39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Other and unspecified postprocedural erectile dysfunction (N52.39: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (N52.39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Total & in Other and unspecified postprocedural erectile dysfunction (N52.39: Free Testosterone (2x) | Total 500–900 ng/dL; Free 110–210 pg/mL (N52.39) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other and unspecified postprocedural erectile dysfunction
Treatment selection for Other and unspecified postprocedural erectile dysfunction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other and unspecified postprocedural erectile dysfunction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile: What a 1,458-Participant Study Found TTh achieved a significant improvement in the IIEF-EFD score of hypogonadal men compared with placebo, especially in those who received testosterone gel, were treated for over 30 weeks, and had no comorbidities. Urologia internationalis • 2022-01-15 • Meta-Analysis | N = 1,458 | 99/100 | PMID 34856556 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
| New Insights on Effect of testosterone replacement therapy on fracture risk in hypogonadal: What a 2,711-Participant Study Found TRT is associated with an increased incidence of predominantly non-major fractures, while the risk of major osteoporotic fractures, including hip and vertebral fractures, was not increased. Maturitas • 2026-06-15 • Meta-Analysis | N = 2,711 | 99/100 | PMID 42066666 ↗ |
Other and unspecified postprocedural erectile dysfunction Patient Community & “People Like Me” Threads
Filter Other and unspecified postprocedural erectile dysfunction community threads and patient logs by age, biological sex, dosage, and treatment duration.